Tolentino, Jarel Elgin
Lytras, Spyros
Ito, Jumpei
Sato, Kei
Funding for this research was provided by:
Japanese Government MEXT Scholarship Research Category (220235)
Japan Science and Technology Agency PRESTO (JPMJPR22R1)
AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers "UTOPIA" (JP223fa627001)
AMED SCARDA Program on R&D of new generation vaccine including new modality application (JP223fa727002)
AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP22fk0108146)
Article History
Received: 21 November 2023
Accepted: 3 April 2024
First Online: 10 April 2024
Declarations
:
: Not applicable.
: Not applicable.
: Spyros Lytras has consulting fees from EcoHealth Alliance. Jumpei Ito has consulting fees and honoraria for lectures from Takeda Pharmaceutical Co. Ltd. Kei Sato has consulting fees from Moderna Japan Co., Ltd. and Takeda Pharmaceutical Co. Ltd. and honoraria for lectures from Gilead Sciences, Inc., Moderna Japan Co., Ltd., and Shionogi & Co., Ltd. The other authors declare no competing interests. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.